Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection. In ...

Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase III drugs for Chronic Obstructive Pulmonary ...

These symptoms included severe functional limitations, requiring frequent exposure to high-dose prednisolone. Mepolizumab was added to the treatment, leading to optimal control of bronchial asthma.

Exacerbations fell with omalizumab and mepolizumab for patients with asthma and obesity. Obesity did not decrease dupilumab’s rate of response in treating asthma. Tezepelumab may address type 2 ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Although their specific mechanisms of action differ, there is as yet no guidance on whether to choose mepolizumab or benralizumab for any given patient. Aims To investigate clinical outcomes of ...

Background Mepolizumab and benralizumab are biologic therapies licensed for the treatment of severe eosinophilic asthma. Mepolizumab is a serum neutralising antibody against interleukin (IL)−5 whereas ...

1 The Phase III MIRRA study demonstrated that patients with EGPA spent more time in remission and had reduced oral corticosteroid (OCS) use with mepolizumab versus placebo. 2 Objectives To evaluate ...